Patents by Inventor Jerome Kosmeder

Jerome Kosmeder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11971337
    Abstract: Disclosed are compositions and methods for inactivating one or more enzymes in a biological sample.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: April 30, 2024
    Assignee: VENTANA MEDICAL SYSTEMS, INC.
    Inventors: James Grille, Brian D. Kelly, Jerome Kosmeder, II, Eric May, Noemi Sebastiao, Pamela Wirth
  • Publication number: 20220026319
    Abstract: Disclosed are compositions and methods for inactivating one or more enzymes in a biological sample.
    Type: Application
    Filed: October 4, 2021
    Publication date: January 27, 2022
    Applicant: VENTANA MEDICAL SYSTEMS, INC.
    Inventors: James Grille, Brian D. Kelly, Jerome Kosmeder, II, Eric May, Noemi Sebastiao, Pamela Wirth
  • Patent number: 11162877
    Abstract: Disclosed are compositions and methods for inactivating one or more enzymes in a biological sample.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: November 2, 2021
    Assignee: Ventana Medical Systems, Inc.
    Inventors: James Grille, Brian D. Kelly, Jerome Kosmeder, II, Eric May, Noemi Sebastiao, Pamela Wirth
  • Publication number: 20180120202
    Abstract: Disclosed are compositions and methods for inactivating one or more enzymes in a biological sample.
    Type: Application
    Filed: November 9, 2017
    Publication date: May 3, 2018
    Inventors: James Grille, Brian D. Kelly, Jerome Kosmeder, II, Eric May, Noemi Sebastiao, Pamela Wirth
  • Patent number: 8877505
    Abstract: Embodiments of a composition for stabilizing fluorescent signal of nanoparticles and methods for its use are disclosed. In some embodiments, the composition has a pH from 7 to 10 and includes borate, protein and/or protein hydrolysate, an amine, a preservative, and a nonionic surfactant. In particular embodiments, the amine is an N-ethanol substituted amine, such as ethanolamine, diethanolamine, triethanolamine, N-methyldiethanolamine, N,N-dimethylethanolamine, or a combination thereof. In some embodiments, a fluorescent particle solution, such as a quantum dot solution or quantum dot conjugate solution, is diluted in the composition and stored at 4° C. In certain embodiments, the fluorescence intensity of the diluted fluorescent particle remains substantially the same when stored at 4° C. for at least one month or at least three months. In particular embodiments, a diluted quantum dot conjugate is used to detect a hybridized probe or a protein antigen.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: November 4, 2014
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Eric May, Alexandra Nagy, Jerome Kosmeder
  • Patent number: 8481270
    Abstract: The present invention provides a method and kit for detection of two or more target molecules in a single tissue sample, such as for gene and protein dual detection in a single tissue sample. Methods comprise treating a tissue sample with a first binding moiety that specifically binds a first target molecule. Methods further comprise treating the tissue sample with a solution containing a soluble electron-rich aromatic compound prior to or concomitantly with contacting the tissue sample with a hapten-labeled binding moiety and detecting a second target molecule. In one example, the first target molecule is a protein and the second is a nucleic acid sequence, the first target molecule being detected by immunohistochemistry and the second by in situ hybridization. The disclosed method reduces background due to non-specific binding of the hapten-labeled specific binding moiety to an insoluble electron rich compound deposited near the first target molecule.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: July 9, 2013
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Richard Gniewek, Michael Farrell, Hiroaki Nitta, Megan Lehrkamp, Jerome Kosmeder, Brian Daniel Kelly, Thomas Grogan, Fabien Gaire, Mary Padilla, Christopher Bieniarz
  • Publication number: 20120122094
    Abstract: Embodiments of a composition for stabilizing fluorescent signal of nanoparticles and methods for its use are disclosed. In some embodiments, the composition has a pH from 7 to 10 and includes borate, protein and/or protein hydrolysate, an amine, a preservative, and a nonionic surfactant. In particular embodiments, the amine is an N-ethanol substituted amine, such as ethanolamine, diethanolamine, triethanolamine, N-methyldiethanolamine, N,N-dimethylethanolamine, or a combination thereof. In some embodiments, a fluorescent particle solution, such as a quantum dot solution or quantum dot conjugate solution, is diluted in the composition and stored at 4° C. In certain embodiments, the fluorescence intensity of the diluted fluorescent particle remains substantially the same when stored at 4° C. for at least one month or at least three months. In particular embodiments, a diluted quantum dot conjugate is used to detect a hybridized probe or a protein antigen.
    Type: Application
    Filed: February 1, 2011
    Publication date: May 17, 2012
    Inventors: Eric May, Alexandra Nagy, Jerome Kosmeder
  • Publication number: 20110136130
    Abstract: The present invention provides a method and kit for detection of two or more target molecules in a single tissue sample, such as for gene and protein dual detection in a single tissue sample. Methods comprise treating a tissue sample with a first binding moiety that specifically binds a first target molecule. Methods further comprise treating the tissue sample with a solution containing a soluble electron-rich aromatic compound prior to or concomitantly with contacting the tissue sample with a hapten-labeled binding moiety and detecting a second target molecule. In one example, the first target molecule is a protein and the second is a nucleic acid sequence, the first target molecule being detected by immunohistochemistry and the second by in situ hybridization. The disclosed method reduces background due to non-specific binding of the hapten-labeled specific binding moiety to an insoluble electron rich compound deposited near the first target molecule.
    Type: Application
    Filed: August 21, 2009
    Publication date: June 9, 2011
    Inventors: Richard Gniewek, Michael Farrell, Hiroaki Nitta, Megan Lehrkamp, Jerome Kosmeder, Brian Daniel Kelly, Fabien Gaire, Mary Padilla, Thomas Grogan, Christopher Bieniarz
  • Publication number: 20070172911
    Abstract: A method and composition are disclosed that are useful for processing biological samples. In one aspect, a biological sample such as a tissue section is treated using a histochemical technique and is contacted with a lipid compound during the process to enhance the definition of cellular and sub-cellular features that are observable in the sample when it is viewed microscopically. In other aspects, a coverslipping composition that includes a lipid compound and a method of coverslipping a sample using the coverslipping composition are disclosed.
    Type: Application
    Filed: January 12, 2007
    Publication date: July 26, 2007
    Inventors: Michael Farrell, Christopher Bieniarz, Kurt Reinhardt, Glen Ward, Jerome Kosmeder, Andrew Ghusson, Eric Walk, Guadalupe Manriquez, Thomas Grogan
  • Publication number: 20070117153
    Abstract: A method is disclosed for making a conjugate of two molecules using a hydrazide thiol linker. In a particular working embodiment, an Fc-specific antibody-enzyme conjugate is made using the method and demonstrated to provide exceptional staining sensitivity and specificity in immunohistochemical and in situ hybridization assays.
    Type: Application
    Filed: November 21, 2006
    Publication date: May 24, 2007
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Casey Kernag, Jerome Kosmeder, Mark Lefever
  • Publication number: 20070072835
    Abstract: A composition and method of preventing or inhibiting tumor growth and, more particularly, of treating a malignant tumor, using prodrugs of plant-derived compounds and derivatives is disclosed. In the method, a composition containing betulinic acid or a betulinic acid derivative is administered in a prodrug form to release betulinic acid or a betulinic acid derivative in vivo at the tumor site.
    Type: Application
    Filed: June 28, 2006
    Publication date: March 29, 2007
    Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: John Pezzuto, Jerome Kosmeder, Ze-Qi Xu, Nian Zhou, Miriam Goldsmith
  • Publication number: 20060246523
    Abstract: Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification.
    Type: Application
    Filed: April 27, 2006
    Publication date: November 2, 2006
    Inventors: Christopher Bieniarz, Jennifer Wong, Mark Lefever, Jerome Kosmeder, Julia Ashworth-Sharpe, Casey Kernag
  • Publication number: 20050158770
    Abstract: A method for preparing a nucleic acid probe is provided. The method comprises forming an activated cytosine or cytidine by a bisulfite catalyzed reaction; and covalently linking a reporter molecule to the activated cytosine or cytidine, wherein said activating step, said covalently linking step, or both are conducted in the presence of microwave energy. Also provided by the invention are nucleic acid probes.
    Type: Application
    Filed: December 21, 2004
    Publication date: July 21, 2005
    Applicant: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Michael Farrell, Jerome Kosmeder, Mark Lefever